The Latest Cardiac and Vascular News
New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder’s immediate and complete closure of the LAA compared to Watchman‡ Findings […]
Abbott will gain an innovative, complementary solution in treating vascular disease through CSI’s leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI’s offering will support Abbott’s ability to provide better care for patients with peripheral and coronary artery disease ABBOTT PARK, Ill. and ST. PAUL, […]
Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 Continues to strengthen portfolio with steady cadence of new product approvals ABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ — Abbott […]
Abbott’s new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease ABBOTT PARK, Ill., Jan. 17, 2023 /PRNewswire/ — […]
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about what drove him to CRG after a long tenure with Abbott.
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott’s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip™ for treating mitral regurgitation Results also demonstrate the benefits of Abbott’s TriClip™ for tricuspid regurgitation, […]
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about how CRG is different from healthcare investment partners in the market.
Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a “patent ductus arteriosus” (PDA) in newborns Study found low adverse event rates following a Piccolo procedure, showing additional benefit of the device that can help babies avoid riskier surgery A […]
– Abbott’s Talisman system seals an opening in the heart known as a “patent foramen ovale” (PFO) to prevent blood clots from passing from the right to the left side of the heart and on to the brain, where they can cause a stroke – The Talisman system builds on […]
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]
